Clinical Trials Yearbook 2013

2nd August 2018 (Last Updated August 15th, 2018 11:10)

To say that it's been a challenging year for clinical trials and the biopharma industry would be an understatement; the continuous struggle for biotechs to obtain funding, diminishing R&D pipeline for big pharma, increasing trend of mergers and acquisitions across the sector, and globally decreasing budgets have caused huge strategic pressures. This, coupled with the ever increasing regulatory scrutiny on clinical practices, enhancing expectations for proactive operational quality, continuously reducing access to patients globally and increasing pressure from competition, means that there is plenty to ensure that the industry stay on their toes! The positive thing about these pressures is that they keep the sector looking and moving forward, searching for new and more efficient ways to achieve goals.